Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

被引：0
|
作者：
John Lauriello
Peter J. Weiden
Carole D. Gleeson
Ankit Shah
Luke Boulanger
Krutika Jariwala-Parikh
Elizabeth Hedgeman
Amy K. O’Sullivan
机构：
[1] Jefferson Health—Sidney Kimmel Medical College,Department of Psychiatry and Human Behavior
[2] Thomas Jefferson University,undefined
[3] Alkermes,undefined
[4] IBM Watson Health,undefined
来源：
CNS Drugs | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1123 / 1135
页数：12
相关论文
共 50 条
  • [1] Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
    Lauriello, John
    Weiden, Peter J.
    Gleeson, Carole D.
    Shah, Ankit
    Boulanger, Luke
    Jariwala-Parikh, Krutika
    Hedgeman, Elizabeth
    O'Sullivan, Amy K.
    CNS DRUGS, 2021, 35 (10) : 1123 - 1135
  • [2] Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
    Citrome, Leslie
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 169 - 186
  • [3] Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
    Maini, Kunal
    Gould, Haley
    Hicks, Jessica
    Iqbal, Fatima
    Patterson, James, II
    Edinoff, Amber N.
    Cornett, Elyse M.
    Kaye, Adam M.
    Viswanath, Omar
    Urits, Ivan
    Kaye, Alan D.
    NEUROLOGY INTERNATIONAL, 2021, 13 (03) : 279 - 296
  • [4] Real-world effectiveness of aripiprazole long-acting injectable
    Pappa, S.
    Barnett, J.
    Mason, K.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S472 - S472
  • [5] Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review
    Chiara Rapinesi
    Georgios D. Kotzalidis
    Lorenzo Mazzarini
    Roberto Brugnoli
    Stefano Ferracuti
    Sergio De Filippis
    Ilaria Cuomo
    Gloria Giordano
    Antonio Del Casale
    Gloria Angeletti
    Gabriele Sani
    Paolo Girardi
    Clinical Drug Investigation, 2019, 39 : 713 - 735
  • [6] Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review
    Rapinesi, Chiara
    Kotzalidis, Georgios D.
    Mazzarini, Lorenzo
    Brugnoli, Roberto
    Ferracuti, Stefano
    De Filippis, Sergio
    Cuomo, Ilaria
    Giordano, Gloria
    Del Casale, Antonio
    Angeletti, Gloria
    Sani, Gabriele
    Girardi, Paolo
    CLINICAL DRUG INVESTIGATION, 2019, 39 (08) : 713 - 735
  • [7] Aripiprazole Lauroxil Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
    Hard, Marjie L.
    Mills, Richard J.
    Sadler, Brian M.
    Turncliff, Ryan Z.
    Citrome, Leslie
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (03) : 289 - 295
  • [8] Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
    Citrome, Leslie
    Correll, Christoph U.
    Cutler, Andrew J.
    Dunbar, Martin
    Hoberg, Amber R.
    Hopkinson, Craig
    Mattingly, Gregory W.
    Mcgrory, James A.
    Rege, Bhaskar
    Weiden, Peter J.
    Mcdonnell, David
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2025, 21 : 575 - 596
  • [9] Long-acting injectable (LAI) antipsychotics in the long-term treatment of schizophrenia
    Fleischhacker, Wolfgang
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 321 - 322
  • [10] Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia
    Potkin, Steven G.
    Preda, Adrian
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 395 - 407
12345